SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " Drugs " 590 found 🔀 AI-powered Shuffle
Officials: Barren County business owner arrested, charged with trafficking drugs out of storefront
Law enforcement agencies served a search warrant that led to a drug trafficking arrest.
Why aren’t health insurers rushing to cover GLP-1 prescriptions for beneficial weight loss?
In theory, GLP-1 receptor agonist drugs like semaglutide and tirzepatide should save a lot of money for the health insurers that pay for them. As it turns out, the lived reality is not keeping pace with the idealistic expectation.
There’s a right way to regulate drugs. Kratom is no exception.
Kratom, social media use in teens, New York's data center moratorium and more, in readers' eyes.
The next step of site-neutral, and a fiery PBM hearing
Medicare proposes to reduce payments to hospitals for certain drugs and imaging services.
Need surgery or prescriptions? How to deal with prior authorization challenges
Prior authorization: Why insurers require approval for some drugs, tests and procedures.
Bristol Myers Squibb Building Life Science Industry’s Most Advanced AI Factory on NVIDIA Vera Rubin
The pharmaceutical company has demonstrated how AI can transform how drugs discovery and is now scaling AI across R&D to accelerate the discovery of next-generation medicines.
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
Opinion | Double standard over GLP-1 drugs hits women especially hard
Women experience the effects of obesity in many ways, including heart disease, certain cancers, fertility challenges, maternal health complications, and more severe menopause symptoms.
Weight-loss drugs may improve job prospects and dating odds for one group
A weight-loss specialist says GLP-1 results boost confidence in job interviews and dating, but the study found no clear improvement in well-being.
Trump officials want to make testosterone drugs easier to prescribe. Is that a good idea?
Officials under President Donald Trump want to make it easier for men to get a prescription for testosterone, the latest shift in a decades-long debate over the benefits and risks of replacing the hormone that affects sex drive, mood and other health factors.
Jillian Michaels warns against social media health advice as ‘healthmaxxing’ trend goes viral
‘Keeping It Real’ podcast host Jillian Michaels discusses the viral ‘healthmaxxing’ trend and GLP-1 drugs on ‘Fox & Friends.’
Sunscreen gets an upgrade | Investors Lab
There are hundreds of brands of sunscreen available in the United States, but not one of them contains an ingredient we all need. Bemotrizinol, a highly effective, broad-spectrum chemical ultraviolet ray blocker, has been available in Europe for decades but absent from U.S. shelves. The regulatory bottleneck was driven by a 2011 U.S. Food and Drug Administration policy classifying sunscreens as drugs. While the classification remains, consumers and innovators can welcome the news that the FDA has officially approved bemotrizinol, effective August 9, 2026. Science News's Meghan Rosen provides the coverage.
Weight-loss drugs didn't improve mental health or job prospects
The non-health benefits haven't been studied as closely as the health benefits.
How Unaffordable is Health Care and What Can We Do About It?
For decades, the cost of medical care, prescription drugs and health insurance has consistently risen faster than general inflation and wage growth, posing financial challenges for government, businesses and people.
GLP-1s are latest wedding trend that has serious implications
Doctors worry the drugs are becoming a wedding fad as online prescribing makes them easier to obtain.
Scientists’ Side Hustle? Using AI and Quantum Computing to Generate New Peptides
Researchers cobbled together funding and time to show how quantum computing could aid in the development of drugs to help underserved populations and combat rare diseases.
Big Medicine threatens your wallet and your health. But there is a solution.
The Break Up Big Medicine Act has bipartisan support, and builds on new laws restricting pharmacy benefit managers.
UK becoming ‘wild west’ for experimental peptides, expert warns
Prof Channa Jayasena says growing online sales of unregulated drugs risk fatalities as responsibility falls between regulators
Waiting for insurance coverage for GLP-1s for weight loss? Keep waiting.
The corporations that pay for private employee health insurance are not ready to swallow the high costs of the enormously popular drugs, said the CEO of CVS Health.
GLP-1 drugs linked to long-term benefits for PAD patients
PAD patients treated with GLP-1 receptor agonists lived longer, stayed out of the hospital more and experienced fewer amputations than those given metformin.
GLP-1 drug popularity is outpacing the science, Madison doctor says
Dr. David Harris at UW-Madison says weight loss drugs like Ozempic, Wegovy and Zepbound are safe, so long as patients get the medications from doctors.
Germany's lower house of parliament passes healthcare reform
Germany's lower house of parliament on Friday approved a bill to overhaul the creaking health insurance system that has drawn fierce opposition from drugs companies which fear tougher pricing measures will harm profitability and reduce investment.
Roche ends two Huntington’s disease drug programmes after disappointing results
⏱️ 10 min read | Roche announced it is stopping development of two of its huntingtin-lowering ASO drugs, tominersen and RG6496. This marks a disappointing end to an important chapter in HD clinical research.
Surprising Mental Health Effects of GLP-1 Weight Loss Drugs
GLP-1 medications may be used to treat select psychiatric disorders.
Sen. Mitch McConnell’s constituents deserve transparency
Mitch McConnell's health, Nixon’s war on drugs, 'Take Me Home, Country Roads' and more, in readers' eyes.
Healthy Returns: Employers aren't expanding coverage of GLP-1 obesity drugs – many are finding ways around it
Around 36% of employers said they provide coverage of GLP-1s for both diabetes and weight loss, the same as 2025 and up from 34% in 2024, the survey said.
Scientists finally crack nature's secret for building better cancer drugs
Researchers have cracked the code behind bacteria's ability to naturally manufacture multiple versions of powerful anti-cancer drugs. The discovery could make it much easier to engineer new cancer treatments inspired by nature, including improved versions of existing medicines.
New weight loss pill beats oral Ozempic in major trial
A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements than the leading oral semaglutide in a major clinical trial. The tablet could offer a more convenient alternative to injectable drugs like Ozempic and Wegovy because it doesn't require refrigeration or special timing with meals. It's also cheaper to manufacture, which could expand access globally.
Oregon eyes $421 million in Medicaid cuts, including fewer benefits and limits on prescription drugs
Major cuts are coming to the Oregon Health Plan, the state’s free healthcare program covering 1.4 million children and low-income adults. But the group of experts Gov. Tina Kotek charged with minimizing the harm of those cuts has given her no definitive recommendations.
How easy is it to get weight-loss drugs online? Secret shoppers from Yale found out.
The quality of care by online providers offering lower-cost knockoff versions of weight loss drugs is an increasingly urgent issue.
Ipsos poll offers new snapshot of Americans' views on health care and GLP-1 drugs
New study changes what scientists know about lithium and bipolar disorder
Lithium is one of the most effective drugs for bipolar disorder. However, its narrow therapeutic window means the difference between an effective dose and a toxic one is small.
A hidden weakness in deadly cancers could lead to powerful new treatments
A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for decades. Scientists found that tumors lacking the RB gene become critically dependent on the protein E2F3 for survival. Blocking E2F3 shut down tumor growth in laboratory models, and existing FDA-approved drugs may be able to exploit this vulnerability. The discovery could pave the way for faster development of more effective therapies.
The New Anthropic Tool That Could Change How Drugs Are Developed
Introducing Claude Science, the AI platform designed to expedite the discovery of promising new therapies. Anthropic will also use it in-house to pursue innovative treatments for 'neglected' diseases.
3 arrested, guns and drugs seized after Birmingham Police shut down ‘illegal business’
Birmingham Police announced they conducted a coordinated operation that resulted in the shutdown of an “illegally operating business.”
Illegal business shut down, guns and drugs found
Illegal business shut down, guns and drugs found
New HHS agenda targeting antidepressants creates pushback
As the Department of Health and Human Services creates new efforts to limit the overprescription of SSRI drugs, psychiatrists are pushing back.
Dr. Oz on Medicare covering weight loss drugs, America's health innovation
Dr. Mehmet Oz discusses health innovation for America's 250th birthday, highlighting a new initiative where Medicare will cover GLP-1 weight loss medications for $50 a month, aiming to reduce health complications.
Anthropic Wants to Make Its Own Drugs With Help from Claude
The AI company is launching preclinical drug programs for overlooked diseases.
Anthropic wants to develop its own drugs
The AI drug boom has a long way to go before reaching patients.
Why you should wash new clothes before wearing; signs that you are aging well; effective leadership in health care; plus other stories with Vanderbilt Health sources
Jami Miller, MD, Professor of Clinical Dermatology, and David Gaston, MD, PhD, Assistant Professor of Pathology, Microbiology and Immunology, are quoted in a Southern Living piece about the importance of washing new clothes before wearing them. Dyes, chemicals, mold and bacteria are all potential troublemakers lurking around your new duds. Parul Goyal, MBBS, Associate Professor of Clinical Medicine, was quoted in a Huff Post story outlining signs that you are aging well. Tae Kon Kim, MD, PhD, Assistant Professor of Medicine, was interviewed by Healio for a story headlined, “Effective leadership in health care ‘starts with listening.’” AAMC News reporter Patrick Boyle interviewed Wes Ely, MD, Professor of Medicine and Critical Care, for a story about ICU delirium. PharmaVoice reporter Kelly Bilodeau interviewed Romney Humphries, PhD, Vice Chair and Executive Medical Director, Clinical Services, for a story about the CDC’s new data that shows an alarming increase in the prevalence of a gene that can make “nightmare bacteria” significantly harder to treat. American Community Media interviewed William Schaffner, MD, Professor of Preventive Medicine, for a piece about Ebola that was reused by several media outlets around the U.S., including The Mississippi Link. Stacie Dusetzina, PhD, Professor of Health Policy, was quoted by The Independent in a story about how Medicare will soon cover weight-loss drugs. Courtney Schadt, MD, Associate Professor of Dermatology, was interviewed by Tennessean reporter Beth Warren, about tanning safety and tanning fads circulating social media. WKRN News 2 interviewed Amanda Peltier, MD, Professor of Neurology, about the correlation between head trauma and ALS following the diagnosis of former Titans running back Chris Johnson.
Trump admin proposes rule it says could save Medicare patients $1.1B on drugs
The change would apply to hospitals that serve low-income patients
Over-40s with obesity have normal-BMI cholesterol and blood pressure levels, study finds
Success of statins and blood-pressure drugs hailed as researchers find some people with obesity were ‘better off’
Statins and blood pressure drugs changing health risks of obesity, study suggests
New research shows obesity patients over 40 are managing blood pressure and cholesterol as well as healthy-weight peers, but younger adults remain at risk.
Healthy Returns: Walmart, CVS step in to help seniors navigate Medicare coverage of obesity drugs
Medicare has started covering obesity drugs for the first time – and companies like Walmart and CVS Health are playing an important role for patients.
‘Beautiful blobs’: synthetic life a step closer as scientists make cells using lab-made DNA
Tiny, quivering spheres designed to feed and multiply raise prospect of artificial organisms to make drugs, food and fuel
Hospital sued after drug addict nurse allegedly causes death of two patients
An emergency department nurse at Heritage Valley Sewickley Hospital is accused of stealing drugs and neglecting patients, causing at least two fatalities. A lawsuit filed by two whistleblowers further alleges that hospital leadership covered for the drug-dependent nurse.
Western Pa. nurse accused in lawsuit of causing 2 patient deaths, stealing drugs
A federal lawsuit accuses Heritage Valley Health System and staff members of enabling alleged crimes by emergency department nurse Nolan Chismire, including drug theft, false insurance claims, and failures in patient care allegedly linked to two deaths.
Ozempic Might Be Making Your Team Less Driven. Here’s the Science
New reports on GLP-1 drugs and the brain’s “wanting” system have direct implications for how leaders motivate, reward, build teams, and sustain culture.
Top GLP-1 prescription indications include sleep apnea, depression and kidney disease, study finds
A report from Trilliant Health looking at payer data found that, as prescriptions for the popular weight loss drugs spike, so rises the number of approved benefits.
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of unapproved drugs popular with followers of Robert F. Kennedy Jr.
GLP-1s 101: What the science says about weight loss, side effects, safety
We asked Stanford Medicine experts to break down everything you need to know about the drugs known as GLP-1s, semaglutide, Ozempic, Wegovy, Zepbound and many more.
Medicare will start covering weight-loss drugs on July 1 for the first time.
Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.
Mental health medications can cause heat sensitivity
Some drugs can impair the body’s ability to cool itself and require extra self-care.
Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know
Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.
Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know.
The Trump administration will launch its pilot program on Wednesday. It lasts 18 months, and estimated costs to taxpayers have not been disclosed.
Could GLP-1 Drugs Help You Live Longer?
Experts are intrigued by the theory. Here’s what early research suggests.
Could GLP-1 Drugs Help You Live Longer?
Experts are intrigued by the theory. Here’s what early research suggests.
Americans keep poisoning themselves with semaglutide, other weight loss drugs
These incidents became much more common after the FDA started approving GLP-1 drugs for chronic weight management in 2021.
Medicare will soon offer some older Oregonians weight loss drugs for $50 a month. Here’s how it works.
Medicare has long excluded coverage of GLP-1s prescribed solely for weight loss.
Medical breakthroughs collide with the health system
The buzziest advances — like personalized gene therapies or AI-discovered drugs — may not deliver.
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
It's one thing to design a pharmaceutical drug. It's another to know if and why it actually works; not on paper or in a computer model, but inside the chaotic world of living systems, where proteins twist ...
Health Subcommittee Markup of 15 Bills Addressing Illicit Drugs and Health Care Price Transparency
The Committee on Energy and Commerce is the oldest standing legislative committee in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee.
CMS projects national health spending grew to $5.7 trillion in 2025
National health spending is projected to have reached $5.7 trillion in 2025, up 7.3% from 2024, according to an analysis by the Centers for Medicare & Medicaid Services published yesterday by Health Affairs. It marks the third consecutive year of growth greater than 7%. CMS projects growth to continue in 2026 due to continued demand for high-cost retail prescription drugs, mostly from individuals with Medicare and private insurance.
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
Researchers invent a laser technique that reveals the hidden forces shaping proteins, advancing a future of precision medicine engineered with quantum precision.
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
U.S. health spending rose sharply in 2025, thanks to GLP-1 use and more care
People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.
People on GLP-1 medications are exercising less
A new study found that people using weight-loss drugs are doing less exercise, despite feeling healthier. Here's how muscle mass and bone density are affected.
Trouble getting weight loss drugs covered by insurance? Here's what to know
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won't cover it, you have options.
“Criminal Approach to Politics”: Trump Ally Abelardo de la Espriella Wins Colombian Presidency
Right-wing Trump ally Abelardo de la Espriella has clinched a narrow victory in Sunday’s runoff presidential election in Colombia, defeating leftist Senator Iván Cepeda, an ally of current President Gustavo Petro. De la Espriella ran a fearmongering, “tough-on-crime” campaign, promising to build mega-prisons inspired by El Salvador’s authoritarian President Nayib Bukele, to bomb “narcoterrorist camps” and to abandon Petro’s peace efforts. His reported victory is also a win for U.S. President Donald Trump, whose administration is waging an intensifying “war on drugs” across Latin America, targeting left-wing leaders like Petro with false allegations and threats of military intervention. “De la Espriella clearly represents a criminal approach to politics: lying, propaganda, coordination and collusion with criminal narcotrafficking, restriction of rights, and money laundering,” says longtime Colombian activist Manuel Rozental. With his victory, says Rozental, “We expect to have military operations and a U.S. intervention within the country. We expect to have human rights abuses. We expect to have militarization. And it’s all for the extraction of resources and the link of drug trafficking to the U.S. government, U.S. interests and global mafia.”
Cities and Schools Are Testing Wastewater for Illicit Drugs
The White House recently endorsed monitoring sewage for evidence of drug use. Critics fear such efforts could violate privacy and stigmatize neighborhoods.
Daveigh Chase's mother says late 'The Ring' star struggled with addiction after back injury: 'She was completely gone'
Daveigh Chase's mother said that 'drugs took hold of' the late 'Lilo & Stitch' actress after she was prescribed painkillers for a back injury she sustained in a motorcycle accident around 2016.
Opinion | We Need to Keep Funding Weird Science
Science turned a serendipitous finding about lizard venom into one of the most important drugs of the century, but that type of research is getting harder to do.
Should everyone be on GLP-1s? What science actually tells us (and doesn't) about the broader health benefits
The laundry list of possible health benefits from GLP-1 drugs seems to get longer by the day, from cancer prevention to combating addiction. But while there’s no question these medications show immense promise beyond their use for diabetes and weight loss, science is still catching up.
Popular weight-loss drugs linked to unexpected male fertility benefit
GLP-1 drugs like semaglutide and liraglutide do not appear to suppress male hormones and may boost fertility in obese men, new research suggests.
Ozempic changed obesity treatment, but experts say the real revolution is next
The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where medications, minimally invasive procedures, surgery, and precision medicine work together to deliver better long-term results.
MUSC Health passes $10B budget, reflecting growth in drugs and population
Medical University of South Carolina and its hospitals and physicians will have a budget that tops $10 billion next fiscal year, driven by the cost of drugs and a growing population in the state.
Assertio completes $166M merger with Zydus following bidding war
The deal leaves Lake Forest-based Assertio, which specializes in oncology drugs, as a wholly-owned subsidiary of Zydus Lifesciences.
Analysis of 352 probiotic supplements finds mismatched microbes across marketed health benefits
Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, ...
Supreme Court limits power of federal government to disarm drug users
The Supreme Court Thursday curbed the power of the federal government to disarm a frequent marijuana user, limiting the scope of a law enacted during the 1960s to keep weapons out of the hands of Americans who regularly use drugs.
NM spent nearly $844M on behavioral health, but 'investment is not yet matching the outcome'
New Mexico has spent $843.5 million since 2022 to rebuild state’s behavioral health system but still faces problems.
Abarca Health And LucyRx To Merge Into Alternative To Big Three PBMs
Abarca Health and LucyRx - two independent pharmacy benefit managers - have agreed to merge asregulators and the public seek a better price on prescription drugs.
Ozempic and Wegovy linked to surprising drop in violent behavior
A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress that cause and effect have not been proven.
Rhode Island health insurers seek double-digit hikes
'Unsustainable’ increases reflect higher cost of prescription drugs and fewer people on the state health exchange.
Central Florida counselor discusses connection between mental health and GLP-1 weight-loss drugs
Licensed mental health counselor Shantala Boss explores the connection between GLP-1 medications, disordered eating, and body image concerns.
GLP-1 and weight-loss drugs: How fast-track health solutions are reshaping FMCG
GLP-1 weight-loss drugs are reshaping FMCG as health, body control, and self-optimization trends redefine consumer behaviour across Europe.
Why healthcare stocks are primed to outperform the market: 2 firms
UBS listed three reasons they like the sector, starting with GLP-1 weight-loss drugs.
Express Scripts sues Tennessee over PBM law that would close specialty pharmacy
The company called the state’s regulation of pharmacy benefit managers “shortsighted,” as it would force the closure of Accredo, a specialty drug dispensary that supplies drugs it says aren’t available anywhere else in the state.
Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies offer lifestyle support so people taking obesity drugs can have the most success losing weight. But employers also want the telehealth providers to limit spending on the drugs.
People taking GLP-1 weight loss drugs like Ozempic started moving less
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
GLP-1 Drugs May Protect Against Cancer— Here’s What That Means For Public Health
New research suggests GLP-1 drugs could reduce cancer risk. A doctor breaks down how that could change public health in the future.
Changes to the NC State Health Plan will make retirees pay more. Here’s what it means for you
Retirees on the state’s Medicare Advantage plans will pay more for hospital stays, specialist visits and some drugs next year.
Scientists Race to Test Treatments as Ebola Outbreak Widens
Trials are beginning on several drugs that have shown promise in preliminary studies against the virus that is causing the current outbreak.
UT Austin researchers create nanoscale Longhorn using DNA origami
UT Austin researchers folded DNA into a nanoscale Longhorn, demonstrating a breakthrough that could help deliver cancer drugs more precisely and speed up the production of advanced materials.
Heart Health Biotech Kardigan Seeks $373.3 Million in US IPO
Kardigan Inc. is seeking to raise $373.3 million in a US initial public offering to help fund three late-stage drugs that target cardiovascular diseases.
Genetically modified worms can now produce and deliver drugs inside a living body, scientists say
In a proof-of-concept lab experiment, scientists demonstrated that intestinal parasites could make and release therapeutic agents inside a living host.
New OMB rule could break science in the United States
The drug that saved your mother. The treatment your doctor recommended. The clinical trial that bought someone you love more time. None of it was inevitable. It required a system built to operate outside politics and sustained over decades, because science doesn’t operate on the timeline of a politician. That system is now under direct threat. The Office of Management and Budget (OMB) has proposed a new rule to regulate all federal grants, not just science, but housing, education, defense, NASA and everything in between, that would fundamentally change how research is conducted in the United States. There have been a lot of fires in the past 16 months, and if everything is an emergency, nothing is an emergency. But this is a very big deal. These rules would strip away the independence that has kept science from becoming a political tool. The good news is there’s still something we can all do. How the grant system was designed to work When I was a new faculty member, I was full of millions of ideas, so I sat down and wrote an NIH proposal. I worked on it for months and thought it was so good. Then I sent it to my mentor. It came back covered in comments. Places where my reasoning wasn’t as airtight as I’d thought, methods that could be stronger, gaps in my thinking that I had been too close to the work to see. It stung, as honest feedback always does, but peer review almost always makes the work better. In fact, it’s the backbone of how American science has functioned for generations. At NIH, submitted proposals go to a panel of scientists who have experience in the field. These are the people who can read research methods and spot their weaknesses, who understand when an experiment is designed well and when it isn’t. Applications are scored rigorously, and often only the top 3-20% of proposals receive funding. The people making funding decisions are required to justify them based on these reviews. To be clear: this is not a perfect system, and good science still goes unfunded more often than any of us would like due to limited resources. There is also criticism that peer review may undervalue bold ideas that are risky but could have high payoffs. But the peer review system is nonetheless a meaningful part of the grant selection process. While thoughtful and careful changes could improve the system, the changes being proposed by OMB will not make things better. The rule that could change everything Through this OMB proposal, the system that helps decide what gets funded is being dismantled. There are many troubling elements buried in this proposal, but three provisions stand out in particular. Each would be damaging alone. Together, they would change what kind of science gets done in America, and who it serves. 1. Political appointees would decide which science gets funded, and peer review would be explicitly sidelined or ignored. The guidelines your doctor follows, the standards that determine what’s in your air and water, the drugs that get approved for your family: all of it starts with a funding decision. Right now, that decision is made by scientists who can evaluate whether the work is actually sound and whether it could move the needle forward. Under this proposal, funding decisions could be made by political appointees. The careful, expertise-driven review process that shapes grant funding would be effectively sidelined. That means that a poorly designed study could get funded simply because someone in a political office liked the sound of it, while rigorous, important work doesn’t get funded because it no longer aligns with the administration’s priorities. In other words, critical work that benefits all of us could now be missed just because it has become politically inconvenient. 2. Grants could be canceled at any point, without warning, in the middle of ongoing work. Say your tax dollars have been paying for a cancer study for two years. The grant was awarded for five years, so the team is mid-experiment. There are three additional years’ worth of answers that could change how the disease is treated for hundreds of thousands of people. With this new rule, the federal government could cancel the remaining funding tomorrow, walk away from the commitment it made with your money, and have no legal obligation to finish what it started. This is a huge waste of money. There are rarely other sources of funding for this work, which means the team, the graduate students, postdocs, and research staff who have dedicated years of their careers to this project could lose their jobs. Patients who have contributed their time to studies may not see it turn into useful learnings for others. Every hour of work already completed could result in nothing useful. Science can take decades to get to tangible outcomes. It needs a stable funding system to flourish. 3. Researchers would have a harder time communicating their findings without pre-approval from the federal government. There is a saying from Sir Mark Walport: “Science isn’t finished until it’s communicated.” Science is no use to anyone if it is kept locked away in the labs that produced the data. The proposed rule could make communicating research findings harder in a number of ways: Make it harder for scientists to widely share their findings in scientific journals. Publication costs, including journal fees that allow for broad public access, could not be paid for by federal funds which is often how scientists pay these costs. Restrict researchers from engaging publicly about how their findings should inform policy or public health guidelines. This would restrict scientists from doing the work that transforms years of lab work into decisions that actually affect people’s lives. Make it harder for scientists to attend conferences. Conferences would now need to be approved by the federal agency at the time of grant award. This disadvantages conferences or publications that are not politically aligned. Conferences are a key way in which scientists learn about work happening in their field so they can collaborate and build on each other’s findings. What good is science with a muzzle? The long-term impact These changes could (and hopefully would) be reversed under the next administration. But by then, damage has been done. Once projects are halted or denied funding by political appointees, people leave their science careers for other paths or even leave the country to do their amazing science elsewhere. You cannot pause a scientific study the way you pause a subscription you decided isn’t useful anymore. You cannot freeze a research team that depends on salaries to feed their families, causing a scramble for replacement funding that, in most cases, simply does not exist. When the money stops, everything stops, and all the work in progress and its potential are lost. Despite all of the language about reducing waste, fraud, and abuse, this new proposed rule increases the administrative burden tremendously. Every researcher watching this unfold will make a rational decision: don’t start anything that will take a decade to finish. This includes not building a team around funding that could vanish, or asking the big questions that need patience and stability to answer. The most consequential science, the kind that produces the treatments and the breakthroughs that reach your doctor’s office twenty years from now, is exactly the science that would be abandoned first. This is still a proposal, so we can all do something Some worry this rule is already a done deal. But by law, OMB is required to open a public comment period. Those comments matter because they inform members of Congress, they can be used in litigation, and they create a public record. So here’s what you can do: Submit a public comment. The public comment period on this proposed change is open until July 13. Anyone can submit a comment, and OMB is required to respond to substantial ones. Each comment must be different to count as distinct; identical comments will be counted only once. Comment as an individual, not on behalf of your organization. Here’s a full resource to help you, with useful examples, but in general: Share a story about how science or federal funding has benefitted you or is involved in your work. Are you or someone you loved a cancer survivor? Do you know someone with Alzheimer’s? Have you received NIH/NSF or other federal funding? All of these can be stories you use to highlight why you care. Explain why you’re worried about these proposed changes. You can use the wording found here or in other resources to help you. Ask them to withdraw this proposed rule. Contact your elected representatives. Congress allocates money to federal agencies to spend, and it has oversight of how that process works. You can let your representatives know this proposed change concerns you and ask them to intervene. There are levers they can push that can help at this moment. Let others know why federal funding matters. This isn’t just about science, but ALL federal grants, including for education systems, defense projects, and more. The process, including the importance of federal funding, is invisible to many. We can all make it more visible by sharing how science benefits us and why we value it. You can also share this article, or any of the resources linked here, to help spread awareness! Bottom line We are quickly losing ground in scientific research in the U.S. More changes, like the proposed rule by OMB, would decimate our ability to conduct research here, leaving us all worse off: fewer treatments for pancreatic cancer, less research on pollution impacts, fewer answers for patients with rare disease, and more unaddressed health needs. The impact will be very real for all of us, regardless of where we stand politically. Using our voices for science is more important than ever. Love, LM Big thanks to Dr. Megan Ranney for reading this over and providing brilliant insights, as always. Dr. Liz Marnik, PhD, is Executive Director of The Evidence Collective at YLE and a science communicator and immunologist working at the intersection of public trust, science, and public health. You can find her on Substack, LinkedIn, Instagram and Threads. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
3 ways GLP-1 drugs could be getting better
Drug companies are racing to catch up to Eli Lilly and Novo Nordisk, seeking to require fewer shots or reduce side effects.